Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in Illinois

If you’re a psychiatrist or psychiatric prescriber watching the GLP-1 boom and wondering whether you can (or should) jump into weight management via telehealth, you’re not alone. The regulatory landscape is complex, rapidly evolving, and varies wildly by state. This guide cuts through the confusion with what you actually need to know about prescribing weight-loss medications remotely — from federal DEA rules to state-specific requirements for obesity treatment.

Bottom line up front: Most psychiatrists can legally prescribe weight-loss drugs like semaglutide (Wegovy/Ozempic) or phentermine via telehealth in many states, but you need to navigate a patchwork of federal controlled-substance rules, state medical board standards, and scope-of-practice considerations. And if you’re a PMHNP? The rules get even trickier.

The Federal Landscape: DEA Rules for Telehealth Prescribing

Let’s start with the big one: Can you prescribe controlled substances via telehealth without an in-person visit?

The Short Answer (2026): Yes, but it’s temporary.

The DEA has extended COVID-era telehealth flexibilities through December 31, 2026. This means you can currently prescribe Schedule II–V controlled substances (including phentermine for weight loss or stimulants for ADHD) to new patients via telemedicine nationwide without first meeting them face-to-face. This extension prevents what the government calls a ‘telehealth cliff’ while permanent regulations are developed.

But here’s the catch: This is explicitly a stopgap measure. The DEA has proposed new rules that will likely require either:

• A ‘special telemedicine registration’ for providers prescribing Schedule III–V controlled substances remotely
• Limits on Schedule II prescribing (like initial 30-day supplies or same-state provider-patient requirements)
• Some form of periodic in-person evaluation requirement

Until those permanent rules drop, the temporary extension holds — but providers should plan for a more restrictive future starting 2027.

GLP-1s Are Different: Here’s the good news for weight loss prescribers: drugs like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are not controlled substances. They’re freely prescribable via telehealth under standard prescribing guidelines — no DEA registration needed (beyond your regular medical license). The federal Ryan Haight Act’s in-person exam requirement simply doesn’t apply to non-controlled medications.

So if you’re sticking to GLP-1s, the federal regulatory burden is minimal. It’s the older appetite suppressants like phentermine (Schedule IV) where you need to pay attention to DEA rules and state variations.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Reality: Where the Rules Actually Bite

Federal law sets the floor, but states can and do impose stricter requirements. Some states maintained in-person exam rules even during the federal waiver. Here’s what you need to know for key markets:

New York: The Strictest Standard

New York currently requires at least one in-person medical evaluation before prescribing any controlled substance to a new patient. This is a 2025 state regulation (10 NYCRR §80.63) that effectively mirrors the pre-COVID Ryan Haight Act at the state level.

Limited exceptions exist:

• Another NY provider examined the patient in person within the past 12 months and shared records
• You’re covering for a colleague who saw the patient in person
• Emergency situation with an existing patient (maximum 5-day supply)

What this means for you: In New York, you cannot start a new patient on phentermine via pure telehealth. You’ll need either a hybrid model (partner with local clinics for initial visits) or stick to non-controlled GLP-1s for remote-only patients.

For non-controlled medications (like GLP-1s, SSRIs, antipsychotics), NY allows full telehealth prescribing with no in-person requirement — as long as it meets standard of care.

New York also requires:

• Checking the state PMP (Prescription Monitoring Program) within 24 hours before every Schedule II–IV controlled substance prescription
• Electronic prescribing for all medications (with very limited exceptions)
• For NPs: After 3,600 hours of supervised practice, you can practice independently — but treating obesity may still be considered outside a PMHNP’s typical scope

Florida: Permissive but Protocol-Heavy

Florida is more telehealth-friendly, with some important nuances:

The telehealth law:

• Allows remote evaluation and prescribing without in-person visits for most services
• Prohibits teleprescribing Schedule II controlled substances — except for psychiatric treatment (Adderall for ADHD is explicitly allowed via telehealth)
• Schedule III–V drugs like phentermine are permitted via telehealth

The obesity treatment rules: This is where Florida gets strict. The Board of Medicine requires:

• Patients must have BMI ≥30 (or ≥27 with comorbidities)
• Initial evaluation (can be via telehealth) including history, physical exam, and necessary tests
• Written informed consent documenting risks of weight-loss medications
• Re-evaluation every 3 months minimum for patients on anti-obesity drugs
• Providing each patient with the state’s ‘Weight-Loss Consumer Bill of Rights’

What this means for you: You can prescribe GLP-1s or phentermine via telehealth to Florida patients, but you need robust documentation and quarterly follow-ups. Florida’s consumer protection laws also require transparent pricing and prohibit guaranteeing specific weight loss results in advertising.

For PMHNPs in Florida: You’ll need physician supervision/collaboration to prescribe weight-loss medications. The physician should ideally have relevant expertise (family practice, endocrinology) rather than just another psychiatrist.

California: Tech-Friendly but Strict on Corporate Practice

California embraces telehealth but has its own compliance hurdles:

Telehealth rules:

• Remote examination meets the ‘appropriate prior examination’ requirement for prescribing
• Must obtain and document telehealth consent (Business & Professions Code §2290.5)
• No specific ban on controlled substances via telehealth — standard of care applies

Prescribing requirements:

• Check CURES PDMP before first Schedule II–IV prescription and every 4 months thereafter
• All prescriptions must be electronic
• Document equivalent clinical information as you would in-person (history, symptoms, relevant vitals)

The CPOM problem: California’s Corporate Practice of Medicine doctrine is a major consideration if you’re thinking about starting a weight-loss telehealth service. Only physician-owned professional corporations can provide medical services — non-physicians can’t independently run a weight-loss clinic. You’ll need proper legal structuring.

NP considerations: California’s AB 890 created a pathway for experienced NPs (≥3 years) to attain independent practice authority as of 2026. But a PMHNP prescribing for obesity might still face scope-of-practice questions unless they obtain additional training or certification.

Big news for 2026: California’s Medi-Cal will stop covering GLP-1 medications for weight loss starting January 2026, framing them as non-covered. This will likely push more patients toward cash-pay telehealth models.

Texas: Standard-of-Care Focused

Texas has reformed its telehealth laws to be relatively permissive:

Key requirements:

• Valid physician-patient relationship can be established via live video or store-and-forward plus audio
• No blanket in-person exam requirement for most prescribing
• Must check Texas PMP (AWARxE) for controlled substances and document it
• Telehealth providers must send a report to the patient’s primary care physician within 72 hours (with patient consent)

For NPs/PAs: Texas requires prescriptive authority agreements with physicians. NPs/PAs cannot prescribe Schedule II substances (except in hospital/hospice settings), but phentermine (Schedule IV) is fine under proper delegation.

What this means for you: Under the current DEA extension, a Texas psychiatrist can prescribe phentermine or GLP-1s via telehealth to new patients. Just ensure you’re using live video (not just a questionnaire), creating proper documentation, and following up appropriately.

Pennsylvania: Defers to Federal Law

Pennsylvania has no comprehensive telehealth statute but generally allows it under professional standards:

The approach:

• Telehealth prescribing is permitted as long as standard of care is met
• Must check PA PDMP before first opioid/benzodiazepine prescription and each time thereafter
• For other controlled substances (stimulants, phentermine): check before first prescription and as clinical judgment dictates

For CRNPs: Collaborative agreements with physicians required; no independent practice yet (despite repeated legislative attempts)

What this means for you: The DEA’s extension is recognized in PA, so telehealth prescribing of controlled substances is currently allowed. Most providers check the PMP for all controlled substances as best practice, even if not strictly mandated by statute.

Illinois: Full Practice Authority Friendly

Illinois has been progressive on telehealth:

Key points:

• Telehealth Act explicitly allows provider-patient relationships via telemedicine
• No in-person exam mandated if telehealth encounter meets standard of care
• Audio-only telehealth permitted in some cases (though video recommended for initial weight-loss evaluation)

For APRNs: Illinois offers Full Practice Authority after 4,000 hours of clinical experience. With FPA, NPs can prescribe Schedule II–V controlled substances independently (with a consultation agreement for Schedule II opioids).

PDMP rules: Must check PMPnow for Schedule II narcotics; other controlled substances not mandated but recommended

What this means for you: Illinois is one of the most telehealth-friendly states for weight management. An experienced PMHNP with FPA could theoretically run an independent telehealth weight-loss practice — though scope-of-practice wisdom still applies.

Psychiatrist Scope of Practice: Can You Actually Do This?

The legal answer: Yes, with caveats.

As a fully licensed physician (MD/DO), you have broad prescribing authority. There’s no separate ‘obesity license’ — any physician can treat obesity as long as they’re competent to do so and follow applicable standards of care.

Many psychiatrists already encounter weight management in practice:

• Addressing antipsychotic-induced weight gain
• Managing binge eating disorder
• Prescribing metformin or GLP-1s to mitigate medication side effects

Legally, this falls within your scope. But — and this is important — medical boards will hold you to the same standards as any physician treating obesity.

What competent obesity treatment looks like:

• Documenting patient meets criteria (BMI ≥30 or ≥27 with comorbidities)
• Obtaining appropriate baseline labs (thyroid function, glucose, lipids as indicated)
• Providing or arranging nutrition and exercise counseling
• Setting realistic expectations and discussing risks/benefits
• Monitoring for side effects and efficacy (monthly early in treatment, then at least quarterly)
• Coordinating with the patient’s primary care physician

Clinical considerations unique to psychiatric prescribers:

• Phentermine is a stimulant — could worsen anxiety, trigger mania in bipolar disorder, or interact with MAOIs
• GLP-1s can cause significant GI side effects that might complicate psychiatric medication absorption
• Many psychiatric medications affect metabolism and weight — you’re ideally positioned to manage this holistically
• Some patients may have eating disorders or body dysmorphia that contraindicate weight-loss medications

Consider additional training: While not required, many psychiatrists pursuing obesity treatment obtain certification through the American Board of Obesity Medicine (ABOM) or complete continuing education in weight management. This bolsters your credibility and demonstrates competence if ever questioned.

The PMHNP Question: Murkier Territory

For Psychiatric-Mental Health Nurse Practitioners, scope of practice is defined by training and certification — and this is where weight-loss prescribing gets complicated.

The issue: PMHNPs are educated and certified to treat mental health conditions. Prescribing purely for obesity (a metabolic condition) might be viewed by some state nursing boards as outside your scope, even if you’re legally authorized to prescribe the medications.

State-by-state considerations:

States requiring physician collaboration for obesity treatment:

• Florida: Psych NPs need physician supervision for practice outside mental health; the supervising physician should have relevant expertise in obesity treatment
• Texas: All NPs need prescriptive authority agreements that specify the medications/conditions they’re treating
• California: NPs operate under Standardized Procedures (unless they’ve achieved AB 890 independent practice status)

States with more NP autonomy:

• Illinois: NPs with Full Practice Authority can practice independently, but should still consider scope-of-practice limitations
• New York: After 3,600 hours, NPs can practice without collaborative agreements — but treating conditions outside your specialty training carries professional risk

Best practices for PMHNPs interested in weight management:

1. Work within an integrated model: Prescribe GLP-1s for patients you’re already treating psychiatrically (addressing medication-induced weight gain, binge eating, etc.)
2. Obtain additional training or certification: ABOM certification, obesity medicine CME, or a post-graduate certificate in weight management
3. Collaborate with appropriate physicians: Partner with a family practice or endocrinology colleague who can provide consultation
4. Be transparent about scope: Document that weight-loss treatment is ancillary to your psychiatric care and that you’re coordinating with the patient’s primary provider
5. Consider state-specific protocols: Some states explicitly allow NPs to treat obesity under physician-developed protocols — work within that framework

The Economics: Why Platforms Beat DIY Marketing

Let’s talk about the business reality of weight-loss telehealth, because regulatory compliance is only half the story.

The DIY marketing trap: Many providers think they can just set up a website, run some Google Ads, and start acquiring weight-loss patients for ‘$30-50 per patient.’ This is fantasy.

The real cost of DIY patient acquisition:

• Google Ads for mental health and weight loss keywords: $15-40+ per click
• Conversion rates: 2-5% of clicks become booked patients (you’re paying for 95-98 wasted clicks)
• Realistic cost per booked patient through PPC: $200-400+ when you factor in click costs, testing/optimization, and no-shows from cold leads
• SEO investment: 6-12 months of consistent content creation, technical optimization, and backlink building before meaningful patient flow — typically $2,000-5,000/month if hiring an agency
• Directory listings: Psychology Today, Zocdoc, etc., charge monthly fees ($100-200+) and you’re competing with hundreds of other providers on the same page
• Zocdoc per-booking fees: $35-100+ per patient, plus monthly subscription costs
• Staff time: Handling inquiries, qualifying leads, managing no-shows — all hidden costs

Total monthly marketing spend for meaningful volume: $3,000-5,000+ with uncertain and delayed results.

The platform advantage: This is where models like Klarity Health make economic sense. Instead of gambling $5,000/month on marketing with no guarantee of results, you pay a standard listing fee only when a qualified patient actually books with you.

What you get with a pay-per-appointment model:

• No upfront marketing spend: Zero monthly retainers or subscription fees
• Pre-qualified patients: Matched to your specialty, credentials, and availability
• No wasted ad spend: You only pay when someone actually shows up (or is billed a listing fee per new patient connection)
• Built-in infrastructure: Telehealth platform, EHR integration, billing support included
• Both insurance and cash-pay flow: Diversified revenue streams
• Schedule control: Set your availability, take time off without wasting ad spend

The math is simple: If you’re paying a listing fee per patient that’s comparable to what you’d spend acquiring that patient through DIY marketing (but without the risk, time, and failed campaigns), it’s a no-brainer — especially when you’re starting out or scaling.

DIY marketing can eventually be cost-effective if you have the budget ($5-10K/month for 6+ months), the expertise (SEO and PPC aren’t easy), and the patience (it takes time to build momentum). Most providers — particularly those juggling clinical work — don’t have all three.

Compliance Best Practices: Staying Out of Trouble

Regardless of which state you’re in or which medications you’re prescribing, these universal best practices will keep you compliant:

1. Verify Patient Location Every Visit

State licensure requirements are based on where the patient is located, not where you are. Document patient location at each encounter and ensure you’re licensed there.

2. Obtain Proper Consent

Many states require telehealth consent (California, Illinois, others). Even if not legally mandated, document that you’ve discussed:

• How telehealth works
• Privacy/security measures
• Limitations of remote examination
• What to do in emergencies

3. Document a Thorough Evaluation

State medical boards reviewing telehealth cases want to see documentation equivalent to an office visit:

• For weight loss: BMI calculation, weight history, diet/exercise attempts, medical history (cardiovascular, thyroid, psychiatric), medication list, contraindications assessment
• For psychiatric treatment: Mental status exam, symptom review, functional impairment, prior treatments
• Vital signs when possible: Blood pressure is particularly important for stimulant medications

4. Follow State-Specific Prescribing Protocols

• Florida: Document quarterly follow-ups and informed consent for weight-loss drugs
• New York: Ensure in-person visits for controlled substances or qualify for an exception
• All states: Check the PDMP as required before prescribing controlled substances

5. Use E-Prescribing and PDMP Systems

Most states now mandate electronic prescribing for controlled substances. These systems are often integrated with PDMP checks, making compliance easier.

6. Coordinate Care

Send visit summaries to patients’ primary care providers (with consent). This is legally required in some states (Texas within 72 hours) and best practice everywhere. For weight-loss patients, PCPs should know about GLP-1 therapy to monitor for interactions and adjust other medications.

7. Maintain Proper Malpractice Coverage

Verify your malpractice insurance covers telehealth services and out-of-state practice if applicable. If you’re expanding into obesity treatment from psychiatric practice, discuss this addition with your insurer.

The Intersection: Weight Management for Psychiatric Patients

Here’s where psychiatrists have a unique value proposition: addressing the metabolic consequences of psychiatric medications.

The clinical reality:

• Second-generation antipsychotics cause significant weight gain (average 10-30 pounds in first year)
• Many mood stabilizers affect metabolism
• Depression and anxiety are independent risk factors for obesity
• Binge eating disorder and other eating disorders require psychiatric expertise

Your integrated approach:

• Prescribe GLP-1s to mitigate antipsychotic-induced weight gain (emerging evidence base)
• Address underlying eating behaviors therapeutically
• Coordinate medication adjustments with metabolic monitoring
• Provide the continuity of care that fragmented telehealth weight-loss services lack

This integrated model:

• Clearly falls within your scope (addressing medication side effects)
• Provides genuine value that standalone weight-loss services can’t match
• Reduces regulatory scrutiny (you’re treating psychiatric patients, not running a pure weight-loss mill)
• Builds on existing relationships (your current patients need this)

Looking Ahead: Regulatory Changes on the Horizon

What to watch for:

DEA Permanent Rules (Expected 2026-2027):

• Special telemedicine registration requirements likely
• Possible prescribing limits for Schedule II substances
• State-specific variations in how these are implemented

State Telehealth Laws:

• More states may follow New York’s lead in requiring in-person exams for controlled substances
• Others may codify permanent telehealth expansions
• Scope-of-practice debates for NPs will continue

Insurance Coverage:

• GLP-1s for weight loss face increasing payer restrictions (like California’s Medi-Cal)
• Telehealth parity laws vary by state and payer type
• Documentation requirements for medical necessity are tightening

Professional Liability:

• As telehealth weight-loss services proliferate, expect increased malpractice claims
• Regulatory boards will scrutinize ‘pill mill’ operations
• Standard of care expectations will continue rising

FAQ: What Providers Are Actually Asking

Q: Can I prescribe Ozempic for weight loss via telehealth to new patients?

A: In most states, yes — semaglutide is not a controlled substance, so federal Ryan Haight Act restrictions don’t apply. But you must:

• Be licensed in the patient’s state
• Conduct an appropriate telehealth evaluation (usually live video)
• Meet your state’s standard of care for obesity treatment
• Follow any state-specific protocols (like Florida’s quarterly follow-up requirement)

Q: Do I need an in-person visit to prescribe phentermine online?

A: It depends on your state:

• Currently (through Dec 2026): Federal DEA waiver allows telehealth prescribing without in-person visits
• New York: Requires in-person exam (with limited exceptions)
• Florida, Texas, California, Pennsylvania, Illinois: Allow telehealth prescribing of phentermine under current rules
• After 2026: Likely more restrictive federal requirements

Q: As a PMHNP, can I offer weight-loss treatment?

A: Legally, maybe. Practically, proceed carefully:

• Check your state’s scope-of-practice definition for PMHNPs
• Most states require NPs to practice within their training/certification
• Consider physician collaboration with someone in family practice or endocrinology
• Additional training (ABOM certification) strengthens your case
• Focus on patients where weight management ties to psychiatric care

Q: What labs do I need before starting GLP-1 therapy?

A: Typical baseline labs include:

• Basic metabolic panel (kidney function)
• Lipid panel
• A1C or fasting glucose
• Thyroid function (TSH)
• Liver function tests (ALT/AST)
• Consider pregnancy test for women of childbearing age (GLP-1s are contraindicated in pregnancy)

Q: How often do I need to see weight-loss patients?

A: Varies by state and standard of care:

• Florida: Minimum every 3 months by law
• General best practice: Monthly for first 3 months (dose titration, side effect monitoring), then every 3 months once stable
• More frequently if significant side effects or comorbidities

Q: Can I use compounded semaglutide?

A: It’s legal but controversial:

• FDA allows compounding of drugs on shortage list (semaglutide was on this list)
• Compounded versions are not FDA-approved (may lack quality controls)
• Many PCPs and specialists are concerned about safety of telehealth-prescribed compounded GLP-1s
• Consider liability implications and patient counseling about differences from brand-name products

Q: What happens if I’m licensed in State A but my patient travels to State B?

A: You must be licensed in the state where the patient is physically located at the time of the telehealth visit. If they’re traveling, they’re technically supposed to wait until they’re back in your licensed state for the appointment — or you need licensure in State B.

Making the Move: Practical Next Steps

If you’re a psychiatrist or psychiatric prescriber considering adding weight management via telehealth to your practice:

1. Choose Your Model:

• Integrated approach: Offer weight management as an extension of your existing psychiatric practice (addressing med side effects, treating patients with binge eating, etc.)
• Dedicated service: Create a separate weight-loss telehealth offering
• Platform partnership: Join an established telehealth platform that handles patient acquisition and infrastructure

2. Get Your Compliance House in Order:

• Verify licenses in all states where you’ll see patients
• Review malpractice coverage
• Set up PDMP access in each state
• Implement e-prescribing with controlled substance capability
• Create compliant informed consent forms

3. Develop Clinical Protocols:

• Inclusion/exclusion criteria (BMI thresholds, contraindications)
• Initial evaluation template
• Baseline lab requirements
• Follow-up schedules
• Side effect monitoring plan
• Coordination with PCPs

4. Consider Additional Training:

• ABOM certification (most comprehensive)
• CME courses in obesity medicine
• GLP-1 prescribing courses
• State-specific telehealth compliance training

5. Solve the Patient Acquisition Problem:

• If going solo: Budget realistically ($3-5K/month for 6+ months) for marketing
• If joining a platform: Evaluate per-patient economics vs. your expected reimbursement

The opportunity in telehealth weight management is real — patient demand is massive, outcomes with GLP-1s are genuinely transformative, and psychiatrists bring unique expertise to the table. But success requires navigating a complex regulatory landscape and making smart business decisions about patient acquisition.

For most providers, joining an established platform that handles compliance, patient acquisition, and infrastructure makes more economic sense than building from scratch. The key is finding a model that lets you focus on clinical care rather than marketing algorithms and state-by-state rule variations.

Sources and References

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026). Official DEA/HHS policy statement on controlled substance telehealth extension. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act). Official state statute governing telehealth practice in Florida (2019, accessed November 2025). http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity. Official Florida Board of Medicine regulation outlining obesity prescribing requirements (Effective August 8, 2022). https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 30, 2024). Detailed legal analysis of state-specific weight-loss prescribing rules (FL, NJ, VA). https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. New York Codes, Rules & Regulations Title 10, §80.63 – NY Department of Health Regulation on Prescribing (Amended May 2025). Official New York regulation detailing controlled substance prescribing requirements including in-person exam rules. https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

Want to join a telehealth platform that handles patient acquisition, compliance, and infrastructure while you focus on clinical care? Klarity Health connects psychiatric and weight management providers with pre-qualified patients nationwide through a simple pay-per-appointment model. No upfront marketing spend, no wasted ad budget — just patients ready to see you. Learn more about joining Klarity’s provider network.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated